{"id":"6c2e2b1c63cb","type":"article","url":"https://hartvaat.nl/2026/02/11/proteogenomische-ontleding-van-nierziekte-en-cardiovasculair-renaal-metabool-syn/","title":"Proteogenomische ontleding van nierziekte en cardiovasculair-renaal-metabool syndroom","title_en":"Proteogenomic dissection of kidney disease and cardiovascular-kidney-metabolic syndrome","category":"chronische nierziekte","category_label":"Nierziekte","professions":["cardioloog","internist"],"tags":["cardio-renaal-metabool","niet-statine-therapie","ras-remmers","statines"],"journal":"Kidney International","doi":"https://www.kidney-international.org/article/S0085-2538(26)00071-2/fulltext","source_url":"https://doi.org/https://www.kidney-international.org/article/S0085-2538(26)00071-2/fulltext","authors":["Haikuo Li"],"significance":5,"published":"2026-02-11","source_date":"2026-02-11","image":"","kennis":[],"congress":"","summary_en":"This review discusses how modern proteogenomic techniques provide new insights into the pathophysiology of kidney disease and the cardiovascular-kidney-metabolic syndrome. The integrated approach advances understanding of the cardiorenal connections first described by Richard Bright in 1836.","created":"2026-07-03T10:25:22Z","updated":"2026-07-03T13:24:48Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"De relatie tussen nier en hart werd al in 1836 beschreven door Richard Bright. Dit overzicht bespreekt hoe moderne proteogenomische technieken nieuwe inzichten bieden in de pathofysiologie van nierziekte en het cardiovasculair-renaal-metabool syndroom.","abstract_original":"The intricate relationship between the kidney and the heart was documented as early as 1836 by Richard Bright,1 who observed cardiac structural changes in patients with advanced kidney disease. Since then, extensive research has solidified the concept of cardiorenal syndrome, clarifying its pathophysiology, therapeutic approaches, and clinical implications. Chronic kidney disease (CKD) significantly elevates the incidence of diabetes, hypertension, and cardiovascular disease. Notably, treatments for CKD, such as sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists, also provide cardioprotective benefits, underscoring the interconnected nature of these conditions."}